Cargando…
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the surface of many cancer cell types, including many cases of non-small cell lung cancer. Erlotinib (Tarceva), an oral small-molecule tyrosine kinase inhibitor, is a so-called t...
Autores principales: | Chen, M-C, Chen, C-H, Wang, J-C, Tsai, A-C, Liou, J-P, Pan, S-L, Teng, C-M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789188/ https://www.ncbi.nlm.nih.gov/pubmed/24052078 http://dx.doi.org/10.1038/cddis.2013.330 |
Ejemplares similares
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
por: Chao, Min-Wu, et al.
Publicado: (2019) -
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
por: Tsai, A-C, et al.
Publicado: (2014) -
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Lin, et al.
Publicado: (2012) -
Correction: Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Li, et al.
Publicado: (2012) -
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo
por: Huang, Han-Li, et al.
Publicado: (2014)